(Q38095682)

28 August 2017

title

A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review (English)

1 reference

28 August 2017

1 reference

1 reference

1 reference

1 reference

B M Frier

1

1 reference

28 August 2017

D Russell-Jones

series ordinal

2

1 reference

28 August 2017

T Heise

series ordinal

3

1 reference

28 August 2017

publication date

1 May 2013

1 reference

Diabetes, Obesity and Metabolism

28 August 2017

published in

1 reference

28 August 2017

volume

15

1 reference

28 August 2017

issue

11

1 reference

28 August 2017

page(s)

978-986

1 reference

Life expectancy in a large cohort of type 2 diabetes patients treated in primary care (ZODIAC-10)

28 August 2017

cites work

1 reference

Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.

21 January 2018

1 reference

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes

21 January 2018

1 reference

Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004.

21 January 2018

1 reference

Fasting plasma glucose variability as a marker of nocturnal hypoglycemia in diabetes: evidence from the PREDICTIVE study

21 January 2018

1 reference

FlexPen: addressing issues of confidence and convenience in insulin delivery

21 January 2018

1 reference

Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial

21 January 2018

1 reference

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

21 January 2018

1 reference

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial

21 January 2018

1 reference

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen

21 January 2018

1 reference

Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin

21 January 2018

1 reference

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

21 January 2018

1 reference

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

21 January 2018

1 reference

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes

21 January 2018

1 reference

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

21 January 2018

1 reference

Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial

21 January 2018

1 reference

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

21 January 2018

1 reference

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

21 January 2018

1 reference

Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem

21 January 2018

1 reference

Barriers to insulin initiation and intensification and how to overcome them

21 January 2018

1 reference

Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study

21 January 2018

1 reference

Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study

21 January 2018

1 reference

Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique

21 January 2018

1 reference

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

21 January 2018

1 reference

Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects

21 January 2018

1 reference

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

21 January 2018

1 reference

Hypoglycemia and cardiovascular risks

21 January 2018

1 reference

Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir

21 January 2018

1 reference

Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes

21 January 2018

1 reference

Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

21 January 2018

1 reference

Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes

21 January 2018

1 reference

Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects.

21 January 2018

1 reference

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

21 January 2018

1 reference

Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes

21 January 2018

1 reference

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12106

1 reference

28 August 2017

1 reference